Clean Science & Technology reported its highest-ever consolidated sales of approximately ₹264 crore in the first quarter of fiscal year 2027 (Q1 FY27), driven by a strategic collaboration with Swiss partner Geneus Chem and a long-term supply agreement with Kemin. Despite geopolitical headwinds impacting raw material supply and shipping availability, the company achieved sequential revenue growth of 7% and year-on-year revenue growth of 10%. The earnings call transcript, released on August 6, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlights significant progress in diversifying its product portfolio through advanced HALS chemistry.

The company’s standalone revenue improved by 5% sequentially to ₹203 crore, primarily due to better realizations across all products. Consolidated EBITDA stood at ₹96 crore with a margin of 37%, while net profit (PAT) was ₹73 crore, reflecting a margin of 28%. Managing Director Siddharth Sikchi noted that while volumes were moderated by supply-side challenges, including a two-week production shutdown due to raw material unavailability in India, demand remained steady. The company successfully mitigated these disruptions by securing safety stocks and optimizing supply chain logistics.

Strategic Partnerships and Product Diversification

A key development during the quarter was the entry into a strategic collaboration with Geneus Chem, a Swiss entity specializing in advanced HALS technologies. This partnership involves technology transfer for patented NOR HALS products, which are higher-grade stabilizers used in harsh agricultural film environments. Clean Science will manufacture these products at its Clean Fino-Chem facility, with commercialization expected by Q3 FY27. The company projects additional revenue of ₹300–350 crore over the next three to four years from this collaboration alone. The arrangement includes co-branding and defined geographical marketing rights to avoid conflict.

Additionally, Clean Science signed a definitive five-year supply contract with Kemin, a global leader in food and feed ingredients. This agreement secures offtake for BHA, BHT, TBHQ, and AP products, increasing Kemin’s procurement from the company by 20% to 40%. Siddharth Sikchi emphasized that this deal provides supply security for both parties and leverages their decade-long relationship. The company is initiating capacity expansion to meet this increased demand.

Operational Updates and Financial Metrics

The HALS segment continues to be a major growth driver, now constituting 22% of total sales. Exports accounted for nearly 50% of HALS sales in Q1 FY27, up from purely domestic sales in the previous year. Volumes for HALS were approximately 1,000 tons, with an improved mix towards higher grades, reducing the reliance on legacy products like HALS 770 from 50% to 35%. The company’s subsidiary, Clean Fino-Chem Limited (CFCL), reached operational self-sustainability, having fully recovered its operating expenses. Total investment in CFCL now stands at approximately ₹850 crore, following a capital infusion of ₹100 crore in the quarter.

Note: Comparative figures derived from management commentary on growth rates.

What the Numbers Show

The divergence between standalone and consolidated performance highlights the impact of the HALS scale-up. While standalone revenue grew modestly due to pricing improvements offsetting volume declines from supply chain issues, consolidated results benefited significantly from the higher-margin HALS business. The reduction in reliance on top four legacy products—from 85% in Q4 FY23 to 60% in Q1 FY27—demonstrates successful portfolio diversification. Furthermore, the stabilization of the hydroquinone and catechol plant positions the company to add incremental revenue streams in the coming quarters, although Performance Chemical 2 is expected to commence commercial operations only in Q3 FY27.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE227W01023/acef25fa-9887-432d-8c62-66641878869e.pdf

Clean Science and Technology Limited reported a consolidated net profit of ₹733.50 million for the quarter ended June 30, 2026, marking a 4.7% sequential increase from the preceding quarter’s profit of ₹582.72 million. The result was underpinned by a 10.5% year-on-year rise in revenue to ₹2,684.32 million and a significant jump in other income. Shareholders are set to receive a final dividend, with payments scheduled for September 30, 2026.

The Board of Directors approved the unaudited standalone and consolidated financial results at its meeting held on August 1, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Price Waterhouse Chartered Accountants LLP issued a limited review report on the results, confirming compliance with Ind AS 34 and other generally accepted accounting principles in India.

Financial Performance

Consolidated revenue from operations stood at ₹2,684.32 million in Q1FY27, compared to ₹2,492.53 million in the immediately preceding quarter and ₹2,428.69 million in the same quarter last year. Other income contributed ₹222.18 million, significantly higher than the ₹27.95 million recorded in the prior quarter.

Total expenses rose to ₹1,930.99 million from ₹1,743.61 million in the previous quarter, primarily due to an increase in cost of materials consumed, which jumped to ₹1,268.48 million from ₹991.34 million. Employee benefits expense also increased to ₹166.28 million, up from ₹38.26 million in the prior quarter. The company noted that executive directors had voluntarily forgone a substantial portion of their performance bonus entitlement in the previous quarter, leading to lower employee benefits expense then.

Standalone net profit was reported at ₹732.91 million, with standalone revenue reaching ₹2,071.04 million. Basic earnings per share (EPS) remained constant at ₹6.90 for both consolidated and standalone results.

Strategic Developments and Governance

The Board co-opted Mr. Krishnakumar Satyanarain Saboo as an Additional Director and recommended his appointment as Whole-time Director for a five-year term from August 1, 2026, to July 31, 2031. He will also serve as Factory Occupier effective August 1, 2026. Mr. Saboo, who has over 37 years of experience and has been associated with the company for more than 11 years, currently serves as Group President (Operations).

Additionally, the Board approved the incorporation of a wholly-owned foreign subsidiary in the Netherlands by Clean Fino-Chem Limited, a step-down subsidiary of Clean Science and Technology Limited. The entity, proposed to be named Clean Science BV or similar, will engage in the trading and distribution of specialty chemicals. It is proposed to be incorporated with an initial capital equivalent to EUR 50,000.

The company also highlighted a long-term strategic collaboration entered into by its subsidiary, Clean-Fino Chem Limited, with Geneus Chem AG on July 16, 2026. The agreement involves the exclusive worldwide manufacturing and supply of advanced grades of HALS products. In return, Geneus Chem AG has agreed to issue warrants exercisable within four years, enabling the subsidiary to acquire a 25% stake in Geneus Chem AG on a fully diluted basis upon exercise.

What the Numbers Show

The divergence between revenue growth and expense inflation warrants attention. While consolidated revenue grew 10.5% year-on-year, total expenses surged 19.3% over the same period. This pressure is largely attributable to raw material costs, which rose 36.3% year-on-year to ₹1,268.48 million. However, the company managed to expand profit before tax by 3.2% year-on-year, suggesting that pricing power or mix improvements partially offset input cost inflation. The significant jump in other income, from ₹134.26 million in Q1FY26 to ₹222.18 million in Q1FY27, also provided a tailwind to the bottom line.

The 23rd Annual General Meeting (AGM) is scheduled for September 12, 2026, via Video Conferencing. The record date for determining dividend entitlement is September 5, 2026, with the register of members closing from September 6 to September 12, 2026.